Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Small Study Of Novartis Asthma Drug Shows Promising Results

XTALKS VITALS NEWS

Asthma

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs.

Tweetables from this article:

Tweet: #Asthma drug could lower inflammatory #biomarkers more effectively when compared to the placebo http://ctt.ec/c_o6b+Asthma drug could lower inflammatory biomarkers more effectively when compared to the placebo.

Tweet: By the year 2020, the US market for #asthma drugs is expected to reach $14 billion http://ctt.ec/P0dpl+By the year 2020, the US market for asthma drugs is expected to reach $14 billion.

Share this!

August 9, 2016 | by Sarah Massey, M.Sc.

An experimental asthma medication developed by Novartis has shown promising results in a recent small investigational study. The results – which were published in the journal, The Lancet Respiratory Medicine – suggest that the drug could lower inflammatory biomarkers more effectively when compared to the placebo.

The trial involved 61 patients who were randomly assigned to receive the experimental drug, called fevipiprant, or a placebo. The drug is a prostaglandin D2 receptor 2 antagonist, and was successful at significantly reducing the eosinophil count in those with moderate to severe asthma.

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs. According to Reuters, the Swiss drugmaker hopes to file for regulatory approval in 2019.



To meet that goal, Novartis will need to conduct further studies involving more patients in order to prove the efficacy of fevipiprant. If approved, the drug could be the first new oral treatment for asthma since the 1950s.

By the year 2020, the US market for asthma drugs is expected to reach $14 billion, according to GBI Research. In 2013, the market was worth $11.7 billion.

While pharma giants GlaxoSmithKline, Merck and AstraZeneca are all major players in the asthma space, Novartis is hoping to gain market share with fevipiprant. As much of the R&D into new asthma therapies has focused on inhaled drugs, most of the top-selling medications for the respiratory condition utilize that form of drug delivery.

The current study was conducted at Glenfield Hospital in Leicester, UK. Fevipiprant was described as having a good safety profile, with no serious adverse events reported.


Keywords: Asthma, Biomarker, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.